Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Boston USA March 8-11, 2020 Back

Tweet

Modeling-Supported Islatravir Dose Selection for Phase 3       Reported by Jules Levin   Deanne Jackson Rudd; Youfang Cao; Pavan Vaddady; Jay A. Grobler; Ernest Asante-Appiah; Tracy Diamond; Stephanie Klopfer; Anjana Grandhi; Peter Sklar; Carey Hwang; Ryan Vargo Merck & Co., Inc., Kenilworth, NJ, USA   CROI: Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)   CROI: WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251 - (03/11/20)   CROI: Weekly Islatravir Protects Monkeys Against IV Challenge With SIV - Mark Mascolini (03/11/20)